Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:17 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1345–1368 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: BE-FAST Clear all

Conditions: Metastatic or Locally Advanced Unresectable Solid Tumors
Interventions: M1774, Niraparib; Drug
Lead sponsor: EMD Serono Research & Development Institute, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 5
States / cities: Boston, Massachusetts • Austin, Texas • Dallas, Texas + 1 more

Conditions: Diabetes Mellitus
Interventions: Mobile Insulin Titration Intervention; Other
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 70 Years
Enrollment: 61 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: New York, New York

Conditions: Healthy Subjects
Interventions: ASP5354, Placebo; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Type 1 Diabetes
Interventions: Ultra-rapid insulin; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Stanford, California

Conditions: Plantar Fasciitis
Interventions: transdermal CBD cream (Tolcylen®, Marlinz Pharma), Matched Placebos; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Diabetes Mellitus
Interventions: Aliskiren + Valsartan; Drug
Lead sponsor: HeartDrug Research LLC; Other
Eligibility: 21 Years to 65 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Glioma, Glioma (Any Grade) in the Brain, Glioblastom WHO Grade 4, Glioblastoma, Glioblastoma (GBM), Grade III Astrocytoma, Grade II Glioma, Grade IV Astrocytoma, Grade IV Glioma, Grade III Glioma
Interventions: Connectome MRI, Neuropsychological testing; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes
Interventions: Ramipril, Candesartan cilexetil, Allopurinol; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 21 Years and older
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2010
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Fasting, Breast Cancer, Survivorship, Breast Cancer Recurrent
Interventions: Fasting; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Brain Metastases From HER2 and Breast Cancer, Advanced HER2-positive Breast Cancer
Interventions: ARRY-380 Twice Daily Dosage, ARRY-380 Once Daily, Trastuzumab; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2023
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Accidental Overdose of Opiate
Interventions: Take home rapid drug test; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years to 35 Years
Enrollment: 93 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: HIV Infections
Interventions: Infant feeding counseling that includes Flash-heat; Procedure
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Transtibial Amputation, Peripheral Artery Disease, Diabetes Mellitus
Interventions: Error-augmentation gait training, Error-correction gait training, Supervised walking; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 40 Years to 89 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Aurora, Colorado • Richmond, Virginia

Conditions: Raynaud, Scleroderma
Interventions: Fasudil; Drug
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Anesthesia
Interventions: Modified Time Principle Induction (MTPI) with rocuronium, RSI succinylcholine; Drug
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Decompensated Heart Failure
Interventions: Reprieve System, furosemide infusion; Device · Drug
Lead sponsor: Reprieve Cardiovascular, Inc; Industry
Eligibility: 22 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 35
States / cities: Irvine, California • Long Beach, California • Sacramento, California + 28 more

Conditions: Obstructive Sleep Apnea
Interventions: Upper airway collapsibility (Pcrit); Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 79 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Diego, California

Conditions: Silicosis, Pneumoconiosis; Silica
Interventions: Tuberculosis test, Chest X-ray, Pulmonary Function Test; Diagnostic Test
Lead sponsor: University of Oklahoma; Other
Eligibility: 30 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Healthy Volunteer
Interventions: Alectinib, Esomeprazole, High Fat and Calorie Meal, Standard Meal; Drug · Other
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Migraine, Cluster Headache, Trigeminal Autonomic Cephalgia, Hemicrania Continua, Paroxysmal Hemicrania, SUNCT, Short-Lasting Unilateral Neuralgiform Headache With Conjunctival Injection and Tearing
Interventions: Oral capsaicin, Topical capsaicin, Intranasal capsaicin, Cold Water Irrigation, Medical Air, Low Flow Oxygen, High Flow Oxygen; Drug · Other
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years and older
Enrollment: 371 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Drug Resistant Epilepsy, Drop Seizures, Generalized Tonic Clonic Seizure, Complex Partial Seizure, Fall Due to Seizure
Interventions: Hövding inflatable helmet; Device
Lead sponsor: Michael A. Gelfand, MD, PhD; Other
Eligibility: 18 Years to 60 Years
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Peripheral Arterial Disease, Intermittent Claudication
Interventions: Home-based leg heat therapy; Device
Lead sponsor: Purdue University; Other
Eligibility: 60 Years and older
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: West Lafayette, Indiana

Conditions: Chronic Kidney Disease, End Stage Renal Disease, Anemia
Interventions: Roxadustat; Drug
Lead sponsor: Kyntra Bio; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2019
U.S. locations: 4
States / cities: Riverside, California • Greenbelt, Maryland • Asheville, North Carolina + 1 more

Conditions: Metabolic Syndrome, Diabetes Mellitus, Non-Insulin-Dependent
Interventions: Randomized pills either containing combination of lycopene and isoflavones (dietary supplements) or Placebo to be taken for 12 weeks, Screening, OGTT, Anthropometrics and Blood pressure, Blood Drawing; Drug · Other
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 2
States / cities: Galveston, Texas

Search by objective public record fields.

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Mobile Insulin Titration Intervention

A Study in Healthy Adult Volunteers to Assess the Safety and Pharmacokinetics of an Investigational Imaging Product

Evaluating the Benefits of Physiologic Insulin Delivery

A Double-Blinded Study on Rapid and Sustained Pain Relief Topical Cannabidiol for Plantar Fasciitis

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

Observational Connectomics in Adults Undergoing Resection of WHO II-IV Glioma

Impact of Diabetes on Left Ventricular Remodeling

Prolonged Nightly Fasting in Breast Cancer Survivors

ARRY-380 + Trastuzuamab for Breast w/ Brain Mets

Rapid Self-Testing to Prevent Fentanyl Overdose Among Young People Who Use Drugs

Feasibility and Pilot Efficacy of Flash-heated Breast Milk to Reduce Maternal-to-Child-Transmission of HIV in Tanzania

Optimizing Gait Rehabilitation for Veterans With Non-traumatic Lower Limb Amputation

A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon

Comparison of Intubation Conditions During Rapid Sequence Induction Obtained With Modified Time Principal Induction With a Standard Intubation Dose of Rocuronium Versus Succinylcholine

Fluid Management of Acute Decompensated Heart Failure Subjects Treated With Reprieve System (FASTR-II) (IDE-G210258)

Determination of Upper Airway Collapsibility During Routine CPAP Titration

Screening Strategy for Early Diagnosis of Silicosis in At-Risk Populations in Oklahoma

A Study Investigating the Effect of Food and Esomeprazole on the Single Oral Dose Pharmacokinetics of Alectinib (RO5424802) in Healthy Volunteers.

Pain Biomarker Study

Novel Helmet Design in Patients With Seizures

A New Heat Therapy Device for Home-based Leg Heating in Patients With Lower-extremity Peripheral Artery Disease

Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease

Effect of Lycopene and Isoflavones on Glucose Metabolism